Clinical Trials Results - National Cancer Institute


	Clinical Trials Search Results

	Quick Links


	Director's Corner Dictionary of Cancer Terms NCI Drug Dictionary Funding Opportunities NCI Publications Advisory Boards and Groups Science Serving People Español

Questions about cancer?

	NCI Highlights


	High Dose Chemotherapy Prolongs Survival for Leukemia Prostate Cancer Study Shows No Benefit for Selenium, Vitamin E Past Highlights



Results: 1 -10 of 10 Show results per page	View Search Criteria \| Help With Results


1.		A Study of E7389 in Advanced/Metastatic Breast Cancer Patients

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Completed				18 and over				Pharmaceutical / Industry				E7389-A001-201 NCT00097721


2.		Phase II Study Of E7389, Halichondrin B Analog, In Patients With Advanced Non-Small Cell Lung Cancer (NSCLC) Who Progressed During Or After Platinum-Based Doublet Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				E7389-A001-202 NCT00100932


3.		A Phase II Study of E7389 in Patients With Breast Cancer, Previously Treated With Anthracycline, Taxane and Capecitabine

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				E7389-G000-211 NCT00246090


4.		Evaluating E7389 in Patients With Hormone Refractory Prostate Cancer With Advanced and/or Metastatic Disease Stratified by Prior Chemotherapy

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				Pharmaceutical / Industry				E7389-G000-204 NCT00278993

Last Modified: 12/19/2007 First Published: 6/9/2006


5.		Phase II Study of E7389 in Patients With Metastatic or Recurrent Squamous Cell Carcinoma of the Head and Neck

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				SWOG-S0618 S0618, NCT00337129

Last Modified: 2/14/2008 First Published: 9/23/2006


6.		Phase II Study of E7389 as Second-Line Therapy in Patients With Locally Advanced, Unresectable, or Metastatic Pancreatic Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Temporarily closed				18 and over				NCI				PMH-PHL-049 7448, NCI-7448, NCT00383760

Last Modified: 1/13/2009 First Published: 11/13/2006


7.		Phase II Study of E7389 in Patients With Recurrent or Progressive Stage IIIB or IV Non-Small Cell Lung Cancer

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase II				Treatment				Closed				18 and over				NCI				CCC-PHII-74 7437, NCT00400829

Last Modified: 11/20/2007 First Published: 10/1/2002


8.		Phase I Study of E7389 in Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				18 and over				NCI				CCC-PHI-39 CHNMC-PHI-39, NCI-5730, NCT00047034, 5730


9.		Study of E7389 Administered Once Every 3 Weeks In Patients With Advanced Solid Tumors

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Completed				over 18				Pharmaceutical / Industry				E7389-A001-102 NCT00069277

	Phase				Type				Status				Age				Sponsor				Protocol IDs

	Phase I				Treatment				Closed				20 to 74				Pharmaceutical / Industry				E7389-J081-105 NCT00326950

Select All on One Page

| | | | | | | |

A Service of the National Cancer Institute